Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped REGN stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Regeneron Pharmaceuticals, Inc. demonstrates strong growth potential driven by a diversified and innovative portfolio, strategic partnerships, and a history of outperforming earnings expectations, despite facing some regulatory and industry-specific challenges. The 1-year, 5-year, and 10-year projections indicate substantial bullish prospects, supported by the company's ability to secure FDA approvals and advance pipeline developments. The saved 1-year distribution is P10 $500, P50 $820, and P90 $950.
Last analyzed · Model: gpt-4o
Regeneron Pharmaceuticals, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $500 | Pessimistic plausible scenario |
| P50 | $820 | Median scenario |
| P90 | $950 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
Regeneron's positive catalysts, including strategic collaborations and FDA approvals, are expected to drive near-term growth. Supply chain challenges and regulatory delays pose some risks. Analysts are optimistic with a strong BUY consensus.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this REGN analysis generated?
March 18, 2026.
Is this a guaranteed REGN prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full REGN stock analysis · REGN sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.